News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
In this case, a largely arrhythmic hormonal signal triggers a rhythmic reception and response in the target tissue, thus changing tissue output rhythms, albeit without affecting core clock rhythms, in response to alterations in endocrine signal tone (or level)
FAQs What are GLP-1 receptor agonists used for
Manja ekspresija receptora glukagona je takoe opisana u drugim tkivima kao to su srce, pankreas, masno tkivo i gastrointestinalni trakt
